Three European biopharma firms are coming together to create one company with a mission to combat antimicrobial resistance (AMR). The new company, Aurobac Therapeutics SAS, was founded by Germany’s Boehringer Ingelheim and Evotec SE, along with France’s bioMérieux.
Posts
Pfizer and Roivant Sciences unveiled a new company called Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.